Table 1.
Patient, tumor, and treatment characteristics.
|
Characteristics |
No replan (n = 81) |
Replan (n = 79) |
Total (n = 160) |
| Disease site, n (%) | |||
| Oropharynx | 28 (34.6) | 25 (31.6) | 53 (33.1) |
| Sinonasal | 8 (9.9) | 19 (24.1) | 27 (16.9) |
| Cutaneous | 19 (23.5) | 7 (8.9) | 26 (16.3) |
| Nasopharynx | 5 (6.2) | 11 (13.9) | 16 (10.0) |
| Oral cavity | 7 (8.6) | 6 (7.6) | 13 (8.1) |
| Salivary gland | 9 (11.1) | 3 (3.8) | 12 (7.5) |
| Other | 5 (6.2) | 8 (10.1) | 13 (8.1) |
| Experience, n (%) | |||
| Early | 32 (39.5) | 18 (22.8) | 50 (31.3) |
| Mature | 49 (60.5) | 61 (77.2) | 110 (68.8) |
| Primary overall stage, n (%) | |||
| I | 19 (23.5) | 1 (1.3) | 20 (12.5) |
| II | 16 (19.8) | 10 (12.7) | 26 (16.3) |
| III | 5 (6.2) | 15 (19.0) | 20 (12.5) |
| IV | 34 (42.0) | 45 (57.0) | 79 (49.4) |
| X | 7 (8.6) | 8 (10.1) | 15 (9.4) |
| Treatment regimen, median (range) | |||
| Dose in GyE (RBE 1.1) | 60 (50-70) | 66 (50-70) | 60 (50-70) |
| Number of fractions | 30 (25-35) | 33 (25-35) | 30 (25-35) |
| Concurrent chemotherapy, n (%) | |||
| No | 50 (61.7) | 28 (35.4) | 78 (48.8) |
| Yes | 31 (38.3) | 51 (64.6) | 82 (51.2) |
| Definitive versus adjuvant, n (%) | |||
| Adjuvant | 57 (70.4) | 39 (49.4) | 96 (60.0) |
| Definitive | 24 (29.6) | 40 (50.6) | 64 (40.0) |
| Primary versus recurrent, n (%) | |||
| Recurrent | 34 (42.0) | 16 (20.3) | 50 (31.2) |
| Primary | 47 (58.0) | 63 (79.7) | 110 (68.8) |
| Lymph node treatment, n (%) | |||
| Bilateral | 26 (32.1) | 43 (54.4) | 69 (43.1) |
| Ipsilateral | 27 (33.3) | 14 (17.7) | 41 (25.6) |
| None | 28 (34.6) | 22 (27.8) | 50 (31.2) |
| Number of beams, n (%) | |||
| 1 | 1 (1.2) | 0 (0) | 1 (0.6) |
| 2 | 10 (12.3) | 3 (3.8) | 13 (8.1) |
| 3 | 49 (60.5) | 36 (45.6) | 85 (53.1) |
| 4 | 21 (25.9) | 34 (43.0) | 55 (34.4) |
| 5 | 0 (0) | 6 (7.6%) | 6 (3.8%) |
Abbreviations: GyE, Gy equivalents; RBE, relative biologic effectiveness.